Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announces it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Myriad’s Precise Tumor Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes a patient’s tumor DNA to discover and target important variants within tumors. Myriad will operate TheraMap: Solid Tumor solely as Precise Tumor moving forward.

Read the full article: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics //

Source: https://www.globenewswire.com/news-release/2024/02/01/2822099/15459/en/Myriad-Genetics-Completes-Acquisition-of-Precise-Tumor-Precise-Liquid-and-Laboratory-from-Intermountain-Precision-Genomics.html

Scroll to Top